ID | 55228 |
FullText URL | |
Author |
Hiroshi, Umemura
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamasaki, Osamu
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaji, Tatsuya
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Otsuka, Masaki
Division of Dermatology, Shizuoka Cancer Center Hospital
Asagoe, Kenji
Department of Dermatology, National Hospital Organization Okayama Medical Center
Takata, Minoru
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Iwatsuki, Keiji
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
|
Abstract | With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5-S-cysteinyl-dopa levels were significantly increased in patients with stages III (n = 38) and IV (n = 20) MM compared with patients with stages 0-II (n = 62) MM. In addition, in patients with stages III and IV MM, serum 5-S-cysteinyl-dopa levels of more than 15.0 nmol/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages III-IV), serum 5-S-cysteinyl-dopa levels exceeded the normal limit of 10.0 nmol/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5-S-cysteinyl-dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.
|
Keywords | 5-S-cysteinyl-dopa
biomarker
lactate dehydrogenase
malignant melanoma
serum 5-S-CD
|
Note | 学位審査副論文
|
Published Date | 2017-04
|
Publication Title |
Journal of Dermatology
|
Volume | volume44
|
Issue | issue4
|
Publisher | Wiley-Blackwell
|
Start Page | 449
|
End Page | 454
|
ISSN | 03852407
|
NCID | AA00696658
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
|
File Version | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1111/1346-8138.13651
|